Skip to content
CancerIndex

Publication

[Immune checkpoint inhibition plus Bacillus Calmette-Guerin (BCG) therapy in BCG-naive high-risk non-muscle-invasive bladder cancer: a critical review in the context of current evidence].

Georgios Gakis, Frank Vom Dorp

Urologie (Heidelberg, Germany)Sep 4, 2026PMID 42697960doi:10.1007/s00120-026-02922-4 English AbstractJournal ArticleReviewpubmedProvenance
Source
PubMed
Retrieved
Sep 15, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260915-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

BACKGROUND: Intravesical Bacillus Calmette-Guerin (BCG) therapy following transurethral resection (TURBT) remains an important standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC). Recent phase III trials have evaluated the addition of immune checkpoint inhibitors (IO) to…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.